Home
>
US Stocks
>
Greenwich LifeSciences Inc
Greenwich LifeSciences Inc
GLSI

Greenwich LifeSciences Inc

$37.896.07%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
39.2
Today Low/High
37.89 / 39.2
52 Week Low/High
$3.26 / $158.07
Market Cap
$533.55M

Company Details

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Organisation
Greenwich LifeSciences Inc
Employees
2
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Greenwich LifeSciences Inc share price today

Can Indians buy Greenwich LifeSciences Inc shares?

How can I buy Greenwich LifeSciences Inc shares from India?

Can Fractional shares of Greenwich LifeSciences Inc be purchased?

What are the documents required to start investing in Greenwich LifeSciences Inc stocks?

We are a SEBI registered investement advisor